A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment.
Prophylactic vaccination against HIV-1 sexual transmission will probably require antibody elicitation at genital mucosal surfaces. However, HIV-1 envelope glycoprotein (Env)-based antigens are weakly immunogenic, particularly when applied mucosally. The polyanion PRO 2000 is safe for human vaginal a...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0015861&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850124674392915968 |
|---|---|
| author | Frank Wegmann George Krashias Kerstin Lühn Karoliina Laamanen Sueli Vieira Simon A Jeffs Robin J Shattock Quentin J Sattentau |
| author_facet | Frank Wegmann George Krashias Kerstin Lühn Karoliina Laamanen Sueli Vieira Simon A Jeffs Robin J Shattock Quentin J Sattentau |
| author_sort | Frank Wegmann |
| collection | DOAJ |
| description | Prophylactic vaccination against HIV-1 sexual transmission will probably require antibody elicitation at genital mucosal surfaces. However, HIV-1 envelope glycoprotein (Env)-based antigens are weakly immunogenic, particularly when applied mucosally. The polyanion PRO 2000 is safe for human vaginal application, and thus may represent a potential formulating agent for vaginal delivery of experimental vaccine immunogens. Based upon its biochemical properties, we hypothesized that PRO 2000 might enhance mucosal immunogenicity of HIV-1 envelope glycoprotein (Env)-based antigens, promoting local and systemic immune responses. Vaginal immunization with Env-PRO 2000 resulted in significantly increased titres of Env-specific mucosal IgA and IgG in mice and rabbits, respectively, compared to Env alone, revealing modest but significant mucosal adjuvant activity for PRO 2000. In vitro, PRO 2000 associated with Env, protecting the glycoprotein from proteolytic degradation in human vaginal lavage. Unexpectedly, PRO 2000 antagonized TLR4 activation, suppressing local production of inflammatory cytokines. Since inflammation-mediated recruitment of viral target cells is a major risk factor in HIV-1 transmission, the immune modulatory and anti-inflammatory activities of PRO 2000 combined with its intravaginal safety profile suggests promise as an HIV-1 mucosal vaccine formulating agent. |
| format | Article |
| id | doaj-art-3f20d7f8cb03461e8e3b8284fcdd3f52 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-3f20d7f8cb03461e8e3b8284fcdd3f522025-08-20T02:34:16ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0161e1586110.1371/journal.pone.0015861A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment.Frank WegmannGeorge KrashiasKerstin LühnKaroliina LaamanenSueli VieiraSimon A JeffsRobin J ShattockQuentin J SattentauProphylactic vaccination against HIV-1 sexual transmission will probably require antibody elicitation at genital mucosal surfaces. However, HIV-1 envelope glycoprotein (Env)-based antigens are weakly immunogenic, particularly when applied mucosally. The polyanion PRO 2000 is safe for human vaginal application, and thus may represent a potential formulating agent for vaginal delivery of experimental vaccine immunogens. Based upon its biochemical properties, we hypothesized that PRO 2000 might enhance mucosal immunogenicity of HIV-1 envelope glycoprotein (Env)-based antigens, promoting local and systemic immune responses. Vaginal immunization with Env-PRO 2000 resulted in significantly increased titres of Env-specific mucosal IgA and IgG in mice and rabbits, respectively, compared to Env alone, revealing modest but significant mucosal adjuvant activity for PRO 2000. In vitro, PRO 2000 associated with Env, protecting the glycoprotein from proteolytic degradation in human vaginal lavage. Unexpectedly, PRO 2000 antagonized TLR4 activation, suppressing local production of inflammatory cytokines. Since inflammation-mediated recruitment of viral target cells is a major risk factor in HIV-1 transmission, the immune modulatory and anti-inflammatory activities of PRO 2000 combined with its intravaginal safety profile suggests promise as an HIV-1 mucosal vaccine formulating agent.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0015861&type=printable |
| spellingShingle | Frank Wegmann George Krashias Kerstin Lühn Karoliina Laamanen Sueli Vieira Simon A Jeffs Robin J Shattock Quentin J Sattentau A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment. PLoS ONE |
| title | A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment. |
| title_full | A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment. |
| title_fullStr | A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment. |
| title_full_unstemmed | A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment. |
| title_short | A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment. |
| title_sort | novel strategy for inducing enhanced mucosal hiv 1 antibody responses in an anti inflammatory environment |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0015861&type=printable |
| work_keys_str_mv | AT frankwegmann anovelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT georgekrashias anovelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT kerstinluhn anovelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT karoliinalaamanen anovelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT suelivieira anovelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT simonajeffs anovelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT robinjshattock anovelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT quentinjsattentau anovelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT frankwegmann novelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT georgekrashias novelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT kerstinluhn novelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT karoliinalaamanen novelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT suelivieira novelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT simonajeffs novelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT robinjshattock novelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT quentinjsattentau novelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment |